Pyridoxine-unresponsive homocystinuria has lifelong implications for health. In this issue, Perreault and colleagues present evidence that orally delivered engineered probiotic Escherichia Coli Nissle SYNB1353 is a promising candidate in reducing homocysteine, with successful trials in mice, monkeys, and humans. However, further probiotic optimization and safety assessments are required.

Original languageEnglish
Pages (from-to)298-300
Number of pages3
JournalCell Host and Microbe
Issue number3
StatePublished - Mar 13 2024


Dive into the research topics of 'Conquering homocystinuria with engineered probiotics'. Together they form a unique fingerprint.

Cite this